DK1812015T3 - Methods for inhibition of nkt cells - Google Patents

Methods for inhibition of nkt cells

Info

Publication number
DK1812015T3
DK1812015T3 DK05851383.9T DK05851383T DK1812015T3 DK 1812015 T3 DK1812015 T3 DK 1812015T3 DK 05851383 T DK05851383 T DK 05851383T DK 1812015 T3 DK1812015 T3 DK 1812015T3
Authority
DK
Denmark
Prior art keywords
nkt cell
treatment
inhibition
methods
nkt cells
Prior art date
Application number
DK05851383.9T
Other languages
English (en)
Inventor
Samuel Strober
Everett Hurteau Meyer
Dale T Umetsu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1812015T3 publication Critical patent/DK1812015T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK05851383.9T 2004-11-02 2005-11-02 Methods for inhibition of nkt cells DK1812015T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US70654805P 2005-08-08 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (1)

Publication Number Publication Date
DK1812015T3 true DK1812015T3 (en) 2013-01-02

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05851383.9T DK1812015T3 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Country Status (11)

Country Link
US (2) US7682614B2 (da)
EP (1) EP1812015B1 (da)
JP (1) JP4948418B2 (da)
CN (1) CN101031307B (da)
AT (1) ATE539757T1 (da)
AU (1) AU2005310247A1 (da)
CA (1) CA2584971C (da)
DK (1) DK1812015T3 (da)
ES (1) ES2378076T3 (da)
PT (1) PT1812015E (da)
WO (1) WO2006060117A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441893C (en) 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
ES2689141T3 (es) * 2010-11-25 2018-11-08 Imnate Sarl Modulación de inmunogenicidad antigénica mediante la adición de epítopos reconocidos por linfocitos T citolíticos naturales
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2023153527A1 (ja) * 2022-02-14 2023-08-17 国立研究開発法人理化学研究所 Ｎｋｔ細胞リガンド含有リポソーム組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5679347A (en) 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
DK0751780T3 (da) 1993-06-21 2003-10-13 Brigham & Womens Hospital Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
CA2302155A1 (en) 1997-09-12 1999-03-18 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
WO2000002923A1 (en) 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
WO2001094949A2 (en) 2000-06-05 2001-12-13 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
WO2001094553A1 (fr) 2000-06-06 2001-12-13 Kirin Beer Kabushiki Kaisha Methode d'amplification de lymphocytes t tueurs naturels
US20020164331A1 (en) * 2000-06-19 2002-11-07 Exley Mark A. Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
DE10193431T1 (de) 2000-08-18 2002-11-21 Mitsubishi Electric Corp Fassung für eine Lampe, Transformator für eine Lampe und Verfahren zur Herstellung eines Transformators für eine Lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
IL140537A0 (en) 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
CA2441893C (en) 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6662434B2 (en) 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
CA2444429A1 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) 2001-05-18 2002-11-21 Wegener William E. Security electronic system
CN1561389A (zh) 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
US8084020B2 (en) 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
EP2273419B1 (en) 2002-06-14 2012-03-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving IL-13 and NK-T cells
US7368142B2 (en) 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
EP1539095A1 (en) 2002-08-27 2005-06-15 Société des Produits Nestlé S.A. Preventing or treating epithelial tissue damage or hair loss
US20060116331A1 (en) 2002-09-27 2006-06-01 Biomira, Inc. Glycosylceramide analogues
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
WO2005014008A2 (en) 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
CA2569590C (en) * 2004-06-11 2014-04-01 Riken Drug having regulatory cell ligand contained in liposome

Also Published As

Publication number Publication date
US8679499B2 (en) 2014-03-25
CN101031307B (zh) 2012-09-05
US7682614B2 (en) 2010-03-23
JP4948418B2 (ja) 2012-06-06
WO2006060117A3 (en) 2007-03-01
AU2005310247A1 (en) 2006-06-08
WO2006060117A2 (en) 2006-06-08
US20060116332A1 (en) 2006-06-01
EP1812015B1 (en) 2012-01-04
EP1812015A4 (en) 2008-02-20
ATE539757T1 (de) 2012-01-15
JP2008518974A (ja) 2008-06-05
PT1812015E (pt) 2012-02-20
EP1812015A2 (en) 2007-08-01
CA2584971C (en) 2013-08-06
CA2584971A1 (en) 2006-06-08
ES2378076T3 (es) 2012-04-04
CN101031307A (zh) 2007-09-05
US20100197613A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
DK1812015T3 (en) Methods for inhibition of nkt cells
MA44693B1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
KR20060132036A (ko) 글루코사민 및 글루코사민/항염증제 뮤츄얼 프로드러그,조성물 및 방법
Ruiz-Miyazawa et al. Hesperidin methylchalcone suppresses experimental gout arthritis in mice by inhibiting NF-κB activation
MA43719B1 (fr) Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
MA42381A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
Jervis et al. New CD1d agonists: synthesis and biological activity of 6 ″-triazole-substituted α-galactosyl ceramides
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
AR064220A1 (es) Formulacion liofilizada mab abeta
EP3885366A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
CN112074298A (zh) Langerin+细胞靶向
Chen et al. Hydrogen treatment protects mice against chronic pancreatitis by restoring regulatory T cells loss
KR20080035997A (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
Shi et al. Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice
Gallardo et al. Evaluation of the bioavailability and metabolism of nitroderivatives of hydroxytyrosol using Caco-2 and HepG2 human cell models
WO2008152260A3 (fr) Nouveaux ligands agonistes des recepteurs rars, utilisation en medecine humaine ainsi qu'en cosmetique
Desrini et al. The effect of quercetin and doxorubicin combination in inhibiting resistance in mcf-7 cell